Strong September for MD IP
MD IP secures a successful outcome for a local client in opposition proceedings before the European Patent Office as the firm’s international patent practice continues to grow.
MD IP moves to a new Warsaw office
MD IP’s international patent practice continues to grow with a move to new offices at Park Avenue in central Warsaw.
Application of G 2/21 in recent Board of Appeal decisions (T 1822/23 and T 432/24)
This post looks at two recent decisions of the EPO Boards of Appeal in which the Boards considered whether the proprietor could rely on an alleged technical effect for inventive step in view of G 2/21. Read more in our latest blog post.
Classes, subclasses and post-grant amendments before the EPO
Narrowing a chemical class of compounds to a sub-class or to a specific compound can be a legitimate strategy for defending a patent before the European Patent Office. However, where the claim in question also defines the class in quantitative terms, such amendments may give rise to objections under Article 123(3) EPC. This article analyses situations in which such amendments may nevertheless result in an extension of the scope of protection, with reference to the relevant EPO case law.
EPO and IP Australia to launch a PCT pilot programme for Australian applicants
From March 2026, EPO and IP Australia will launch a two-year PCT pilot programme enabling Australian applicants to select the EPO as ISA and IPEA. Read more in our latest news item.
EPO fees to increase on 1 April 2026
The EPO has announced increases to several official fees effective from 1 April 2026. This overview explains which fees are affected, which remain unchanged, and how the revised amounts compare with current levels.